Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT04328181

Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)

Sponsor: Hospices Civils de Lyon

View on ClinicalTrials.gov

Summary

This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection. Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints, earl/temporal bone, colorectal carcinosis.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

339

Start Date

2021-01-29

Completion Date

2026-01-29

Last Updated

2024-04-04

Healthy Volunteers

Conditions

Diabetic Foot Ulcer Coronary Artery Disease Parenchymatous; Pneumonia Kidney Stone Inner Ear Disease Brain Stroke Joint Diseases Diabetes Adrenal Incidentaloma Hyperaldosteronism Macroadenoma Interstitial Lung Disease Intracranial Arteriovenous Malformations

Interventions

DEVICE

Spectral Photon Counting Computed Tomography (SPCCT)

For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition: * Tube potential 120 kVp; * Tube current time product of 150 mAs; * Gantry revolution time 0.33 s; * Automatic exposure control (angular and longitudinal) combined xyz-axis; * Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;

DEVICE

DECT (Dual Energy CT)

The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters: * Base platform : iCT scanner * Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp * Tube current (mA) : 10 - 300 * Spatial Resolution : \> 30 lp/cm, ≤ 250 µm * Z-coverage isocenter (mm) : 20 mm * FOV (mm) : 500 * Minimum rotation time : 0.33 s/rotation * Acquisition modes : Axial, Helical, Step \& Shoot

Inclusion Criteria: * Patients presenting following one of following medical conditions: 1. Asymptomatic type 1 or 2 diabetes as regard to cardiovascular risks 2. Diabetic foot ulcer 3. Adrenal glands lesions: Adrenal incidentaloma or hyperaldosteronism or macroadenoma 4. Urinary stone(s) 5. Known Coronary artery disease: Stent imaging or control of calcified plaques 6. Diffuse Interstitial Lung Diseases: Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Ground Glass Opacification, Chronic Thromboembolic Pulmonary Hypertension 7. Conductive hearing loss 8. Brain stroke (late or post thrombectomy) 9. Intracranial arteriovenous malformation treated with coils or Onyx 10. Joints diseases in haemophilia 11. Ear/temporal bone 12. Colorectal carcinosis 13. Dissection aortique de type A opérée ou de type B non opérée, hématome intramural * Patient has accepted to participate to the study and has signed the written consent; * Pre-menopausal women only: Negative urinary pregnancy test on the day of imaging before the administration of study drug; * Patient is affiliated to the French social security Exclusion Criteria: * Contraindication to the use of iodine containing contrast media (including subjects with suspicion for/or known to have NSF) (if injection); * History of severe allergic or anaphylactic reaction to any allergen including drugs and contrast agents (as judged by the investigator, taking into account the intensity of the event); * History of delayed major or delayed cutaneous reaction to Iomeron injection * Estimated Glomerular Filtration Rate (eGFR) value \< 30 mL/min/1.73 m2 derived from a serum creatinine result within 1 month before the imaging for examinations with contrast agent. * Any subject on hemodialysis or peritoneal dialysis; * Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery); * Pregnant or nursing (including pumping for storage and feeding); * Patient under guardianship, curatorship or safeguard of justice.

Locations (1)

Hôpital Cardiologique Louis Pradel - Hospices Civils de Lyon

Bron, Avenue Doyen Lépine, France